PET/CT在恶性黑色素瘤免疫检查点抑制剂治疗评估中的研究进展  

The Research Progress of PET/CT in Evaluation of ImmuneCheckpoint Inhibitors for Malignant Melanoma

作　　者：柳宇 丁颖[1] 张立 邓银倩 兰晓莉[1] 曹卫[1] LIU Yu;DING Ying;ZHANG Li;DENG Yinqian;LAN Xiaoli;CAO Wei(Department of Nuclear Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Province Key Laboratory of Molecular Imaging,Key Laboratory of Biological Targeted Therapy,the Ministry of Education,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院核医学科分子影像湖北省重点实验室生物靶向治疗教育部重点实验室,湖北武汉430022

出　　处：《标记免疫分析与临床》2022年第8期1421-1426,共6页Labeled Immunoassays and Clinical Medicine

基　　金：科技部国家重点研发计划(编号:2017YF013302);分子影像湖北省重点实验室开放基金(编号:2020fzyx023)。

摘　　要：恶性黑色素瘤是一种发生在皮肤或其他器官的高度侵袭性肿瘤,易发生局部复发和远处转移,晚期患者预后差,5年生存率低。近年来,免疫疗法取得了前所未有的进展,显著改善了恶性黑色素瘤患者无进展生存期和总生存期。但不同个体免疫治疗反应模式复杂多样,这对临床疗效评价和治疗决策带来了挑战。正电子发射断层显像/计算机断层扫描(positron emission tomography/computed tomography,PET/CT)是一种将解剖形态成像与功能代谢成像完美融合的分子影像检查技术,在评价恶性黑色素瘤免疫治疗疗效及治疗反应模式中显示出潜在的优势,有望指导临床治疗。本文综述了PET/CT成像在恶性黑色素瘤免疫检查点抑制剂治疗评估中的研究现状及进展。Malignant melanoma is a highly aggressive tumor of the skin or other organs,which is prone to local recurrence and distant metastasis.The prognosis of advanced patients is poor and the 5-year survival rate is low.In recent years,immunotherapy has achieved an unprecedented progress,with significantly improved progression-free survival and overall survival in patients with malignant melanoma.However,the complexity and diversity of immunotherapy response patterns in different individuals pose challenges to clinical efficacy evaluation and treatment decision-making.PET/CT is a molecular imaging technology that can integrate anatomical morphological imaging with functional metabolic imaging,showing potential advantages in evaluating the therapeutic efficacy and therapeutic response modes of malignant melanoma.This method is expected to guide clinical treatments.This article reviews the current status and progress of PET/CT imaging in the evaluation of immune checkpoint inhibitors for malignant melanoma.

关 键 词：恶性黑色素瘤 免疫治疗 PET/CT 免疫检查点抑制剂 

分 类 号：R739.5[医药卫生—肿瘤]